Studies have been undertaken to judge the effectiveness of Acthar® Gel (repository corticotropin injection [RCI]) in the tetrodotoxin (TTX) model of early-life-induced epileptic spasms. Repository corticotropin injection (RCI) is broadly used in the United States to deal with childish spasms. A serious element of RCI is N25 deamidated ACTH. Additionally, we hoped to supply some perception into the attainable function circulating corticosteroids play in spasm cessation by evaluating the RCI dose-response relationships for spasm suppression to RCI-induced corticosterone launch from the adrenal gland. Spasms have been induced by persistent TTX infusion into the neocortex starting on postnatal day 11.
Repository corticotropin injection (RCI) dosages have been between Eight and 32 IU/kg/day. Drug titration protocols have been used, and comparisons have been made to injections of a automobile gel. Video/EEG recordings (24/7) monitored the drug’s results repeatedly for as much as 2 months. Tetrodotoxin (TTX)-infused management rats have been monitored for a similar interval of time. In separate experiments, the identical dosages of RCI got to rats and 1 h later plasma was collected and assayed for corticosterone. The value of care included MS-related inpatient, outpatient, and remedy prices. Treatment response was outlined as no proof of extra relapse therapy or process claims inside 30 days after therapy.
A parallel examine in contrast the consequences of 1-day and 10-day RCI remedies on circulating corticosterone. Results confirmed that RCI was ineffective at dosages of 8, 12, and 16 IU/kg/day however eradicated spasms in 66% of animals handled with 24 or 32 IU/kg/day. Treating animals with 32 IU/kg/day alone produced the identical diploma of spasms suppression as noticed throughout the titration protocols. In rats that had hypsarrhythmia-like exercise, RCI eradicated this irregular interictal EEG sample in all rats that grew to become seizure-free. In phrases of plasma corticosterone, 1- and 10-day remedies with RCI produced comparable will increase in this hormone and the degrees elevated linearly with rising dosages of RCI.
This stood in sharp distinction to the sigmoid-like dose-response curve for decreases in spasm counts. Our outcomes additional validate the TTX model as related for the examine of childish spasms. The model ought to be helpful for investigating how RCI acts to get rid of seizures and hypsarrhythmia. Dose-response outcomes recommend that both very excessive concentrations of circulating corticosteroids are required to abolish spasms or RCI acts by a distinct mechanism. In the oblique remedy comparability of six eligible scientific trial research, the chances of attaining efficacy outcomes have been 5 to eight instances larger with RCI than with tetracosactide and 14 to 16 instances larger than CCMC.
A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms
Infantile spasms is a uncommon illness characterised by distinct seizures and hypsarrhythmia. Adrenocorticotropic hormone (ACTH) is on the market as a pure product (repository corticotropin injection, [RCI]; Acthar® Gel) and as artificial analogs. RCI is a naturally-sourced advanced combination of purified ACTH analogs and different pituitary peptides accredited by the United States Food and Drug Administration as a monotherapy for the remedy of childish spasms. RCI is usually used in the United States. Outside the United States, artificial analogs of ACTH-synthetic ACTH1-24 (tetracosactide) and artificial ACTH1-39 (corticotropin carboxymethyl-cellulose [CCMC])-are used.
The efficacy of RCI could differ from that of artificial ACTH remedies primarily based on the construction of peptide; nonetheless, no head-to-head scientific trials have in contrast the efficacy of RCI and artificial ACTH remedies. A scientific overview and oblique remedy comparability of scientific trials was carried out to evaluate the comparative efficacy of RCI and artificial ACTH remedies in childish spasms.
A search was carried out in MEDLINE, EMBASE, and Cochrane databases by September 30, 2020. Relevant scientific trials on RCI or artificial ACTH remedy and reporting both cessation of spasms or decision of hypsarrhythmia, individually or as a mixed final result have been included. A Bayesian oblique remedy comparability utilizing a fixed-effects model was used for comparative efficacy. Of 473 citations screened, 21 research have been reviewed qualitatively. This translated to a threat discount of 10% to 14% and 40% to 50% with RCI versus tetracosactide and CCMC, respectively.
For each two to 5 sufferers handled, RCI improved efficacy outcomes in one extra affected person in comparison with artificial ACTH (adjusted quantity needed-to-treat).Based on the out there restricted proof, outcomes recommend RCI could also be extra efficacious for childish spasms than artificial ACTH remedies. Our findings present a blueprint to tell the design of future potential research for the remedy of childish spasms.
Quality evaluation of real-world knowledge repositories throughout the info life cycle: A literature overview
Data high quality (DQ) have to be constantly outlined in context. The attributes, metadata, and context of longitudinal real-world knowledge (RWD) haven’t been formalized for high quality enchancment throughout the info manufacturing and curation life cycle. We sought to finish a literature overview on DQ evaluation frameworks, indicators and instruments for analysis, public well being, service, and high quality enchancment throughout the info life cycle. The overview adopted PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) pointers.
Databases from well being, bodily and social sciences have been used: Cinahl, Embase, Scopus, ProQuest, Emcare, PsycINFO, Compendex, and Inspec. Embase was used as an alternative of PubMed (an interface to go looking MEDLINE) as a result of it consists of all MeSH (Medical Subject Headings) phrases used and journals in MEDLINE in addition to extra distinctive journals and convention abstracts. A mixed knowledge life cycle and high quality framework guided the search of revealed and grey literature for DQ frameworks, indicators, and instruments. At least 2 authors independently recognized articles for inclusion and extracted and categorized DQ ideas and constructs. All authors mentioned findings iteratively till consensus was reached.
 AAV2-LacZ Control Virus |
|
AAV-342 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 2. |
 AAV1-Luc Control Virus |
|
AAV-321 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 1. |
 AAV3-Luc Control Virus |
|
AAV-323 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 3. |
 AAV4-Luc Control Virus |
|
AAV-324 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 4. |
 AAV5-Luc Control Virus |
|
AAV-325 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 5. |
 AAV6-Luc Control Virus |
|
AAV-326 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Luciferase control virus of AAV serotype 6. |
 AAV1 Null Control Virus |
|
AAV-351 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 1. |
 AAV3 Null Control Virus |
|
AAV-353 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 3. |
 AAV4 Null Control Virus |
|
AAV-354 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 4. |
 AAV5 Null Control Virus |
|
AAV-355 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 5. |
 AAV6 Null Control Virus |
|
AAV-356 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Null (empty) control virus of AAV serotype 6. |
 AAV1-GFP Control Virus |
|
AAV-301 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 1. |
 AAV3-GFP Control Virus |
|
AAV-303 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 3. |
 AAV4-GFP Control Virus |
|
AAV-304 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 4. |
 AAV5-GFP Control Virus |
|
AAV-305 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 5. |
 AAV6-GFP Control Virus |
|
AAV-306 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: GFP control virus of AAV serotype 6. |
 AAV1-Cre Control Virus |
|
AAV-311 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 1. |
 AAV3-Cre Control Virus |
|
AAV-313 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 3. |
 AAV4-Cre Control Virus |
|
AAV-314 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 4. |
 AAV5-Cre Control Virus |
|
AAV-315 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 5. |
 AAV6-Cre Control Virus |
|
AAV-316 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Cre control virus of AAV serotype 6. |
 AAV1-LacZ Control Virus |
|
AAV-341 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 1. |
 AAV3-LacZ Control Virus |
|
AAV-343 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 3. |
 AAV4-LacZ Control Virus |
|
AAV-344 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 4. |
 AAV5-LacZ Control Virus |
|
AAV-345 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 5. |
 AAV6-LacZ Control Virus |
|
AAV-346 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: LacZ control virus of AAV serotype 6. |
 Lenti-III-PGK-Luc Control Virus |
|
LV088 |
ABM |
4 x 500 ul |
EUR 195 |
) saCas9 Nuclease AAV Virus (AAV2) |
|
K209 |
ABM |
2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml |
EUR 375 |
|
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
) Adeno-Associated Virus 2, VP1 (AAV2) |
|
MBS633442-005mg |
MyBiosource |
0.05mg |
EUR 995 |
Adeno-Associated Virus 2, VP1 (AAV2) |
|
MBS633442-5x005mg |
MyBiosource |
5x0.05mg |
EUR 4330 |
) Adeno-Associated Virus 2, VP1, VP2 (AAV2) |
|
MBS600010-005mg |
MyBiosource |
0.05mg |
EUR 960 |
Adeno-Associated Virus 2, VP1, VP2 (AAV2) |
|
MBS600010-5x005mg |
MyBiosource |
5x0.05mg |
EUR 4180 |
 scAAV1-GFP Control Virus |
|
AAV-331 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 1. |
 scAAV2-GFP Control Virus |
|
AAV-332 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 2. |
 scAAV3-GFP Control Virus |
|
AAV-333 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 3. |
 scAAV4-GFP Control Virus |
|
AAV-334 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 4. |
 scAAV5-GFP Control Virus |
|
AAV-335 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 5. |
 scAAV6-GFP Control Virus |
|
AAV-336 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
|
Description: Self-complementary GFP control virus of AAV serotype 6. |
) Adeno-Associated Virus 2 Replicase (AAV2 Replicase) |
|
MBS600022-01mg |
MyBiosource |
0.1mg |
EUR 975 |
Adeno-Associated Virus 2 Replicase (AAV2 Replicase) |
|
MBS600022-5x01mg |
MyBiosource |
5x0.1mg |
EUR 4245 |
Adeno-Associated Virus 2 Replicase (AAV2 Replicase) |
|
MBS602012-005mg |
MyBiosource |
0.05mg |
EUR 975 |
Adeno-Associated Virus 2 Replicase (AAV2 Replicase) |
|
MBS602012-5x005mg |
MyBiosource |
5x0.05mg |
EUR 4245 |
Adeno-Associated Virus 2 Replicase (AAV2 Replicase) |
|
MBS602367-005mg |
MyBiosource |
0.05mg |
EUR 1005 |
Adeno-Associated Virus 2 Replicase (AAV2 Replicase) |
|
MBS602367-5x005mg |
MyBiosource |
5x0.05mg |
EUR 4375 |
) Adeno-Associated Virus 2, VP1, VP2, VP3 (AAV2) |
|
MBS602359-005mg |
MyBiosource |
0.05mg |
EUR 970 |
Adeno-Associated Virus 2, VP1, VP2, VP3 (AAV2) |
|
MBS602359-5x005mg |
MyBiosource |
5x0.05mg |
EUR 4210 |
Adeno-Associated Virus 2, VP1, VP2, VP3 (AAV2) |
|
MBS613487-025mL |
MyBiosource |
0.25mL |
EUR 1000 |
Adeno-Associated Virus 2, VP1, VP2, VP3 (AAV2) |
|
MBS613487-5x025mL |
MyBiosource |
5x0.25mL |
EUR 4345 |
Adeno-Associated Virus 2, VP1, VP2, VP3 (AAV2) |
|
MBS604703-005mg |
MyBiosource |
0.05mg |
EUR 1145 |
Adeno-Associated Virus 2, VP1, VP2, VP3 (AAV2) |
|
MBS604703-5x005mg |
MyBiosource |
5x0.05mg |
EUR 5000 |
 ELISA Kit) Human Adeno-Associated Virus 2 (AAV2) ELISA Kit |
|
abx050302-100g |
Abbexa |
100 µg |
Ask for price |
Human Adeno-Associated Virus 2 (AAV2) ELISA Kit |
|
abx050302-200g |
Abbexa |
200 µg |
Ask for price |
Human Adeno-Associated Virus 2 (AAV2) ELISA Kit |
|
abx050302-50g |
Abbexa |
50 µg |
EUR 493.75 |
 KRV Virus Positive Control |
|
MBS412091-1mL |
MyBiosource |
1mL |
EUR 175 |
KRV Virus Positive Control |
|
MBS412091-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Zika Virus Negative Control |
|
MBS412678-05mL |
MyBiosource |
0.5mL |
EUR 100 |
Zika Virus Negative Control |
|
MBS412678-5x05mL |
MyBiosource |
5x0.5mL |
EUR 305 |
 Zika Virus Positive Control |
|
MBS412728-05mL |
MyBiosource |
0.5mL |
EUR 195 |
Zika Virus Positive Control |
|
MBS412728-5x05mL |
MyBiosource |
5x0.5mL |
EUR 730 |
 Foamy Virus Negative Control |
|
MBS412663-05mL |
MyBiosource |
0.5mL |
EUR 100 |
Foamy Virus Negative Control |
|
MBS412663-5x05mL |
MyBiosource |
5x0.5mL |
EUR 305 |
 Foamy Virus Positive Control |
|
MBS412713-05mL |
MyBiosource |
0.5mL |
EUR 195 |
Foamy Virus Positive Control |
|
MBS412713-5x05mL |
MyBiosource |
5x0.5mL |
EUR 730 |
 HSV-1 Virus Control Stock |
|
20-4810020 |
Quidel |
Single Use, 400 µL, shipped frozen |
Ask for price |
|
Description: Genetically Engineered BHK Cells |
 HSV-2 Virus Control Stock |
|
20-4820020 |
Quidel |
Single Use, 400 µL, shipped frozen |
Ask for price |
|
Description: Genetically Engineered BHK Cells |
 Zika Virus NS1 Control Antigen |
|
BA149R01 |
Genovis AB |
1 mg |
EUR 947 |
 Measles Virus IgG Control Serum |
|
C102G |
Genovis AB |
3 mL |
EUR 105 |
 Measles Virus IgM Control Serum |
|
C102M |
Genovis AB |
3 mL |
EUR 105 |
 Rubella Virus IgG Control Serum |
|
C129G |
Genovis AB |
3 mL |
EUR 105 |
 Rubella Virus IgM Control Serum |
|
C129M |
Genovis AB |
3 mL |
EUR 105 |
 Mouse K Virus Positive Control |
|
MBS412089-1mL |
MyBiosource |
1mL |
EUR 195 |
Mouse K Virus Positive Control |
|
MBS412089-5x1mL |
MyBiosource |
5x1mL |
EUR 720 |
 Zika Virus NS5 Positive Control |
|
MBS543408-5Applications |
MyBiosource |
5Applications |
EUR 335 |
Zika Virus NS5 Positive Control |
|
MBS543408-5x5Applications |
MyBiosource |
5x5Applications |
EUR 1350 |
 Zika Virus NS1 Positive Control |
|
MBS5400765-5Applications |
MyBiosource |
5Applications |
EUR 335 |
Zika Virus NS1 Positive Control |
|
MBS5400765-5x5Applications |
MyBiosource |
5x5Applications |
EUR 1350 |
 Zika Virus NS2 Positive Control |
|
MBS5400766-5Applications |
MyBiosource |
5Applications |
EUR 335 |
Zika Virus NS2 Positive Control |
|
MBS5400766-5x5Applications |
MyBiosource |
5x5Applications |
EUR 1350 |
 Zika Virus NS3 Positive Control |
|
MBS5400767-5Applications |
MyBiosource |
5Applications |
EUR 335 |
Zika Virus NS3 Positive Control |
|
MBS5400767-5x5Applications |
MyBiosource |
5x5Applications |
EUR 1350 |
 Lenti-III-UBC-GFP Control Virus |
|
LV027 |
ABM |
4 x 500 ul |
EUR 195 |
 Lenti-III-PGK-GFP Control Virus |
|
LV028 |
ABM |
4 x 500 ul |
EUR 195 |
 Rat Hanta Virus Positive Control |
|
MBS412088-1mL |
MyBiosource |
1mL |
EUR 175 |
Rat Hanta Virus Positive Control |
|
MBS412088-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 West Nile Virus Negative Control |
|
MBS412656-05mL |
MyBiosource |
0.5mL |
EUR 100 |
West Nile Virus Negative Control |
|
MBS412656-5x05mL |
MyBiosource |
5x0.5mL |
EUR 305 |
 West Nile Virus Positive Control |
|
MBS412706-05mL |
MyBiosource |
0.5mL |
EUR 195 |
West Nile Virus Positive Control |
|
MBS412706-5x05mL |
MyBiosource |
5x0.5mL |
EUR 730 |
 Control) Epstein-Barr Virus (EBV) Control |
|
MBS568624-1mL |
MyBiosource |
1mL |
EUR 300 |
Epstein-Barr Virus (EBV) Control |
|
MBS568624-25mL |
MyBiosource |
25mL |
EUR 2830 |
Epstein-Barr Virus (EBV) Control |
|
MBS568624-5x25mL |
MyBiosource |
5x25mL |
EUR 12475 |
 Mouse Zika Virus Positive Control |
|
MBS412086-05mL |
MyBiosource |
0.5mL |
EUR 175 |
Mouse Zika Virus Positive Control |
|
MBS412086-5x05mL |
MyBiosource |
5x0.5mL |
EUR 645 |
 Rat Sendai Virus Positive Control |
|
MBS412130-1mL |
MyBiosource |
1mL |
EUR 175 |
Rat Sendai Virus Positive Control |
|
MBS412130-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Mouse Hanta Virus Positive Control |
|
MBS412087-1mL |
MyBiosource |
1mL |
EUR 175 |
Mouse Hanta Virus Positive Control |
|
MBS412087-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Mouse Sendai Virus Positive Control |
|
MBS412108-1mL |
MyBiosource |
1mL |
EUR 175 |
Mouse Sendai Virus Positive Control |
|
MBS412108-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 SERION ELISA Avidity control Rubella Virus Avidity Control IgG |
|
MBS191655-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 Lenti-III-EF1alpha-GFP Control Virus |
|
LV046 |
ABM |
4 x 500 ul |
EUR 195 |
 Mouse Polyoma Virus Positive Control |
|
MBS412112-1mL |
MyBiosource |
1mL |
EUR 175 |
Mouse Polyoma Virus Positive Control |
|
MBS412112-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Rat Pneumonia Virus Positive Control |
|
MBS412129-1mL |
MyBiosource |
1mL |
EUR 175 |
Rat Pneumonia Virus Positive Control |
|
MBS412129-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Rabbit Sendai Virus Positive Control |
|
MBS412177-1mL |
MyBiosource |
1mL |
EUR 175 |
Rabbit Sendai Virus Positive Control |
|
MBS412177-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Hamster Sendai Virus Positive Control |
|
MBS412174-1mL |
MyBiosource |
1mL |
EUR 175 |
Hamster Sendai Virus Positive Control |
|
MBS412174-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Mouse Pneumonia Virus Positive Control |
|
MBS412106-1mL |
MyBiosource |
1mL |
EUR 175 |
Mouse Pneumonia Virus Positive Control |
|
MBS412106-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Zika Virus Human IgA Assay Control |
|
BC149A |
Genovis AB |
1 mL |
EUR 105 |
 Zika Virus Human IgG Assay Control |
|
BC149G |
Genovis AB |
1 mL |
EUR 105 |
 Zika Virus Human IgM Assay Control |
|
BC149M |
Genovis AB |
1 mL |
EUR 105 |
 Mouse Ectromelia Virus Positive Control |
|
MBS412109-1mL |
MyBiosource |
1mL |
EUR 175 |
Mouse Ectromelia Virus Positive Control |
|
MBS412109-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Rabbit Pneumonia Virus Positive Control |
|
MBS412176-1mL |
MyBiosource |
1mL |
EUR 175 |
Rabbit Pneumonia Virus Positive Control |
|
MBS412176-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Hamster Pneumonia Virus Positive Control |
|
MBS412171-1mL |
MyBiosource |
1mL |
EUR 175 |
Hamster Pneumonia Virus Positive Control |
|
MBS412171-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 Dengue Virus Human IgG Assay Control |
|
BC114G |
Genovis AB |
1 mL |
EUR 105 |
 Dengue Virus Human IgM Assay Control |
|
BC114M |
Genovis AB |
1 mL |
EUR 105 |
 Influenza A Virus IgA Control Serum |
|
C1231A |
Genovis AB |
3 mL |
EUR 105 |
 Influenza A Virus IgG Control Serum |
|
C1231G |
Genovis AB |
3 mL |
EUR 105 |
 Influenza A Virus IgM Control Serum |
|
C1231M |
Genovis AB |
3 mL |
EUR 105 |
 Influenza B Virus IgA Control Serum |
|
C1232A |
Genovis AB |
3 mL |
EUR 105 |
 Influenza B Virus IgG Control Serum |
|
C1232G |
Genovis AB |
3 mL |
EUR 105 |
 Influenza B Virus IgM Control Serum |
|
C1232M |
Genovis AB |
3 mL |
EUR 105 |
 Simian Virus 40 PCR Positive Control |
|
MBS412587-025mL |
MyBiosource |
0.25mL |
EUR 1500 |
Simian Virus 40 PCR Positive Control |
|
MBS412587-5x025mL |
MyBiosource |
5x0.25mL |
EUR 6545 |
 Mumps Virus Nucleoprotein Control Antigen |
|
BA103R01 |
Genovis AB |
1 mg |
EUR 1016 |
 Positive Control) Rat Minute Virus (RMV) Positive Control |
|
MBS412193-1mL |
MyBiosource |
1mL |
EUR 175 |
Rat Minute Virus (RMV) Positive Control |
|
MBS412193-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 PCR Control) Mouse Hepatitis Virus (MHV) PCR Control |
|
MBS412554-01mL |
MyBiosource |
0.1mL |
EUR 1500 |
Mouse Hepatitis Virus (MHV) PCR Control |
|
MBS412554-5x01mL |
MyBiosource |
5x0.1mL |
EUR 6545 |
 Measles Virus Nucleoprotein Control Antigen |
|
BA102R01 |
Genovis AB |
1 mg |
EUR 1016 |
 Zika Virus Protein 2K Positive Control |
|
MBS5400768-5Applications |
MyBiosource |
5Applications |
EUR 335 |
Zika Virus Protein 2K Positive Control |
|
MBS5400768-5x5Applications |
MyBiosource |
5x5Applications |
EUR 1350 |
 Mumps/Parotitis Virus IgG Control Serum |
|
C103G |
Genovis AB |
3 mL |
EUR 105 |
 Mumps/Parotitis Virus IgM Control Serum |
|
C103M |
Genovis AB |
3 mL |
EUR 105 |
 Kilham Rat Virus PCR Control, Parvovirus |
|
MBS412557-025mL |
MyBiosource |
0.25mL |
EUR 1500 |
Kilham Rat Virus PCR Control, Parvovirus |
|
MBS412557-5x025mL |
MyBiosource |
5x0.25mL |
EUR 6545 |
 Guinea Pig Sendai Virus Positive Control |
|
MBS412175-1mL |
MyBiosource |
1mL |
EUR 175 |
Guinea Pig Sendai Virus Positive Control |
|
MBS412175-5x1mL |
MyBiosource |
5x1mL |
EUR 645 |
 EZ‐Seneca Valley Virus A Control Set |
|
TC-9080-096 |
Tetracore |
each |
EUR 90 |
The 120 included articles yielded ideas associated to contextual (knowledge supply, custodian, and consumer) and technical (interoperability) elements throughout the info life cycle. Contextual DQ subcategories included relevance, usability, accessibility, timeliness, and belief. Well-tested computable DQ indicators and evaluation instruments have been additionally discovered. A DQ evaluation framework that covers intrinsic, technical, and contextual classes throughout the info life cycle permits evaluation and administration of RWD repositories to make sure health
